Editas Medicine, Inc. (0IFK.L)
USD 1.46
(-4.63%)
USD 1.46
(-4.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -169.18 Million USD | 25.12% |
| 2022 | -225.95 Million USD | -16.98% |
| 2021 | -193.14 Million USD | -43.24% |
| 2020 | -134.84 Million USD | 4.32% |
| 2019 | -140.92 Million USD | -23.91% |
| 2018 | -113.72 Million USD | 5.17% |
| 2017 | -119.93 Million USD | -23.4% |
| 2016 | -97.18 Million USD | -175.23% |
| 2015 | -35.31 Million USD | -177.54% |
| 2014 | -12.72 Million USD | -143.74% |
| 2013 | -5.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -66.99 Million USD | -179.57% |
| 2024 Q2 | -71.9 Million USD | -7.33% |
| 2024 Q3 | -62.14 Million USD | 8.67% |
| 2023 Q4 | -23.96 Million USD | 46.77% |
| 2023 FY | -169.18 Million USD | 25.12% |
| 2023 Q1 | -50.96 Million USD | 19.68% |
| 2023 Q2 | -44.09 Million USD | 13.48% |
| 2023 Q3 | -45.01 Million USD | -2.1% |
| 2022 Q2 | -54.23 Million USD | -6.87% |
| 2022 FY | -225.95 Million USD | -16.98% |
| 2022 Q1 | -50.75 Million USD | -21.97% |
| 2022 Q4 | -63.44 Million USD | -10.3% |
| 2022 Q3 | -57.52 Million USD | -6.06% |
| 2021 Q4 | -41.6 Million USD | -6.0% |
| 2021 Q1 | -56.88 Million USD | 13.65% |
| 2021 Q2 | -55.4 Million USD | 2.61% |
| 2021 Q3 | -39.25 Million USD | 29.15% |
| 2021 FY | -193.14 Million USD | -43.24% |
| 2020 Q1 | -46.61 Million USD | -18.25% |
| 2020 FY | -134.84 Million USD | 4.32% |
| 2020 Q4 | -65.87 Million USD | -832.83% |
| 2020 Q3 | 8.98 Million USD | 128.68% |
| 2020 Q2 | -31.33 Million USD | 32.77% |
| 2019 Q3 | -34.58 Million USD | 2.98% |
| 2019 FY | -140.92 Million USD | -23.91% |
| 2019 Q4 | -39.42 Million USD | -13.98% |
| 2019 Q2 | -35.64 Million USD | -14.03% |
| 2019 Q1 | -31.26 Million USD | -19.08% |
| 2018 Q3 | -16.25 Million USD | 59.0% |
| 2018 Q4 | -26.25 Million USD | -61.48% |
| 2018 FY | -113.72 Million USD | 5.17% |
| 2018 Q1 | -31.55 Million USD | 13.4% |
| 2018 Q2 | -39.65 Million USD | -25.66% |
| 2017 FY | -119.93 Million USD | -23.4% |
| 2017 Q1 | -30.62 Million USD | 21.44% |
| 2017 Q2 | -26.11 Million USD | 14.73% |
| 2017 Q3 | -26.74 Million USD | -2.43% |
| 2017 Q4 | -36.44 Million USD | -36.24% |
| 2016 Q4 | -38.98 Million USD | -84.19% |
| 2016 FY | -97.18 Million USD | -175.23% |
| 2016 Q3 | -21.16 Million USD | -10.23% |
| 2016 Q2 | -19.2 Million USD | -7.63% |
| 2016 Q1 | -17.83 Million USD | -44.18% |
| 2015 Q2 | -10.39 Million USD | -101.43% |
| 2015 Q3 | -7.38 Million USD | 28.99% |
| 2015 Q1 | -5.16 Million USD | 0.52% |
| 2015 Q4 | -12.37 Million USD | -67.61% |
| 2015 FY | -35.31 Million USD | -177.54% |
| 2014 FY | -12.72 Million USD | -143.74% |
| 2014 Q3 | -3.13 Million USD | -42.5% |
| 2014 Q4 | -5.18 Million USD | -65.49% |
| 2014 Q2 | -2.2 Million USD | 0.0% |
| 2014 Q1 | -2.2 Million USD | 0.0% |
| 2013 FY | -5.22 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dynavax Technologies Corporation | -37.02 Million USD | -356.9% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -3110.875% |
| Perrigo Company plc | 151.9 Million USD | 211.377% |
| Illumina, Inc. | -1.06 Billion USD | 84.174% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 102.467% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 63.266% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.798% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 108.557% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -52.946% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 104.18% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -278.761% |
| Waters Corporation | 817.67 Million USD | 120.69% |
| Biogen Inc. | 1.29 Billion USD | 113.046% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 38.256% |
| Evolus, Inc. | -49.23 Million USD | -243.633% |
| Adicet Bio, Inc. | -152.03 Million USD | -11.275% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -39.249% |
| bluebird bio, Inc. | -244.26 Million USD | 30.738% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -8.754% |
| FibroGen, Inc. | -281.81 Million USD | 39.967% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 112.532% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -275.313% |
| Homology Medicines, Inc. | -48.25 Million USD | -250.598% |
| Geron Corporation | -193.94 Million USD | 12.768% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 40.044% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -130.197% |
| Myriad Genetics, Inc. | -123.7 Million USD | -36.767% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -67.793% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 67.168% |
| Zoetis Inc. | 3.06 Billion USD | 105.513% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -250.998% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 115.56% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 187.009% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.928% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -332.102% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 52.172% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 38.704% |
| Verastem, Inc. | -92.08 Million USD | -83.725% |
| Nektar Therapeutics | -137.42 Million USD | -23.108% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 27.022% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -73.774% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 36.831% |
| OPKO Health, Inc. | -157.02 Million USD | -7.744% |
| Exelixis, Inc. | 170.88 Million USD | 199.003% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 167.43% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 257.697% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -203.431% |
| uniQure N.V. | -282.87 Million USD | 40.191% |
| Imunon, Inc. | -21.03 Million USD | -704.458% |
| Blueprint Medicines Corporation | -486.27 Million USD | 65.209% |
| Insmed Incorporated | -709.62 Million USD | 76.159% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 150.117% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 56.785% |
| TG Therapeutics, Inc. | 20.63 Million USD | 919.953% |
| Incyte Corporation | 620.52 Million USD | 127.264% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 76.71% |